The biotech licenses a China-developed anti-B7-H3 ADC.
ApexOnco Front Page
Recent articles
Armed with $75m the company takes a risky asset into the clinic.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
Full data from Edge-Gastric are presented at ESMO.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
The first TUB-040 data come just after Tubulis raised €308m.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
